Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Support

This activity is supported by an educational grant from GlaxoSmithKline.

“D” is for Diagnosis® - Cracking the Case in Rare Disorders with Respiratory Symptoms: Practical Approaches to Identification and Clinical Management

Release Date: October 25, 2021
Expiration Date: October 25, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in unusual disorders caused by hypereosinophilia. Eosinophilic disorders are a broad range of conditions with extremely varied pathophysiologies and clinical presentations. They can range from asymptomatic or mild to severe and fatal, making this a complex and difficult medical area. They are defined by organ dysfunction induced by activated eosinophils that affect 1 or more organs and by varying degrees of increased eosinophil numbers in the blood. Eosinophilic disorders encompass allergic diseases (eg, eosinophilic asthma), autoimmune diseases (eg, eosinophil granulomatosis with polyangiitis (EGPA)) and hypereosinophilic syndrome (HES). Novel therapies targeting IL5, IL4, IL13, and immunoglobulin E are now being investigated.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

Pulmonologists, physician assistants, nurse practitioners, and other health care professionals who treat patients with severe asthma and/or other eosinophilic diseases will be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Analyze the underlying pathogenesis of eosinophilic disorders
  • Develop a differential diagnosis for management of patients with eosinophilic disorders
  • Apply efficacy and safety data for emerging therapies for patients with eosinophilic disorders
  • Implement evidence-based guidelines in managing patients with eosinophilic disorders

Faculty, Staff, and Plannrs’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies. 

Program Chair

Cristina Saura, MD, PhD
Michael E. Wechsler, MD, MMSc
Department of Medicine
Division of Pulmonary, Critical Care & Sleep Medicine
Director, NJH Cohen Family Asthma Institute
National Jewish Health
Denver, CO

Disclosures: Grant Research Support: Sanofi, AstraZeneca, Teva; Consultant: AstraZeneca, Amgen, GlaxoSmithKline, Sanofi, Genzyme, Regeneron, Boehringer Ingelheim, Novartis, Genentech, Pulmatrix, Teva, Equillium, CytoReason, resTORbio, Cohero Health, Cerecor, Incyte, Sound Biologics, Kinaset Therapeutics.


Yelena Y. Janjigian, MD
Praveen Akuthota, MD
Associate Professor of Medicine
Division of Pulmonary, Critical Care & Sleep Medicine
University of California San Diego Health
San Diego, CA

Disclosures: Grant/Research Support: AstraZeneca, GlaxoSmithKline, Regeneron; Consultant: AstraZeneca, GlaxoSmithKline.

Maurice Pérol, MD
Anna Kovalszki, MD
Clinical Associate Professor
Division of Allergy and Clinical Immunology
Department of Internal Medicine
University of Michigan Health
Ann Arbor, MI

Disclosures: Grant/Research Support: NATRON study, AstraZeneca, official site (University of Michigan); Consultant: GlaxoSmithKline.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By